ORGS
Orgenesis Inc.·Healthcare
0.60
275.000%(+0.44)
Close PriceLast Updated: — ET
52W L: $0.0252W H: $5.89
ORGS NEWS
newsfilecorp.com
Mar 26
Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio
Plano, Texas--(Newsfile Corp. - March 26, 2026) - Okogen Inc., a biotechnology company developing antiviral therapeutics, today announced the acquisition of the global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc. (OTC: ORGS), strengthening the company's lead ophthalmic program and establishing a foundation for expansion into additional antiviral indications. The acquisition expands the company's development pipeline beyond ocular infections into a set of focused therapeutic areas: eyecare, systemic infectious disease, dermatology and medical countermeasures for high-consequence pathogens such as filoviruses, which form the core pillars of Okogen's Ranpirnase Platform.
defenseworld.net
Feb 13
Critical Contrast: UCB (OTCMKTS:UCBJF) versus Orgenesis (NASDAQ:ORGS)
Orgenesis (NASDAQ: ORGS - Get Free Report) and UCB (OTCMKTS:UCBJF - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability. Insider and Institutional Ownership 22.6% of Orgenesis shares are held
defenseworld.net
Feb 6
Orgenesis (NASDAQ:ORGS) Stock Price Up 300% – Time to Buy?
Orgenesis Inc. (NASDAQ: ORGS - Get Free Report) shares rose 300% during mid-day trading on Thursday. The stock traded as high as $0.60 and last traded at $0.60. Approximately 100 shares traded hands during trading, a decline of 84% from the average daily volume of 636 shares. The stock had previously closed at $0.15. Orgenesis
